FDA Drug Approvals, Ophthalmology — 2019 Midyear Review

Mary L Windle, PharmD


August 08, 2019

Notable new ophthalmology approvals

Xeomin (incobotulinumtoxinA) was approved as first-line treatment of blepharospasm.

Eylea (aflibercept intravitreal) is now approved for all stages of diabetic retinopathy.

Rocklatan (netarsudil/latanoprost) was approved for reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Avaclyr (acyclovir ophthalmic) was approved as a new dosage administration route for herpes simplex virus (HSV-1 and HSV-2).


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.